Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.
Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.